Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Enweida (envafolimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

3DMed, Alphamab, Ascletis, Glenmark, Simcere

Drug class:

PD-L1 inhibitor

Related drugs:

atezolizumab (236)

durvalumab (200)

benmelstobart (12)

sugemalimab (7)

imsapepimut and etimupepimut, adjuvanted (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

cosibelimab-ipdl (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

›

MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B	envafolimab Sensitive: B - Late Trials envafolimab Sensitive : B
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	envafolimab Sensitive: C2 – Inclusion Criteria envafolimab Sensitive : C2	envafolimab Sensitive: C2 – Inclusion Criteria envafolimab Sensitive : C2
HER-2 negative	Gastric Adenocarcinoma	HER-2 negative	Gastric Adenocarcinoma	envafolimab Sensitive: C3 – Early Trials envafolimab Sensitive : C3	envafolimab Sensitive: C3 – Early Trials envafolimab Sensitive : C3